Business
Sernova Announces First Closing of Private Placement
(via TheNewswire) Offering Increased to $3,500,000 LONDON, ONTARIO -...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces First Closing of Private Placement(via TheNewswire)\n \n \nOffering Increased to $3,500,000\n\n \n \nLONDON, ONTARIO - TheNewswire - August 19, 2019 - Sernova Corp. (TSXV:SVA) (FSEPSH) (OTC:SEOVF), a clinical-stage regenerative medicine company, is pleased to announce that it has completed a first closing of $2,333,500 of its non-brokered private placement, (which was announced on July 25, 2019), of which $64,000 was closed under the \"Existing Shareholder Exemption.\"\n\n\n \nIn addition, the Company announces that it is increasing the maximum offering by an additional $500,000, for a total offering of $3,500,000 of Units. Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one common share purchase warrant (\"Warrant\"). Each Warrant will be exercisable into one share at a price of $0.30 per share for a period of 36 months.\n\n\n \nThe Company plans to close the balance of the placement in the coming weeks.\n\n\n \nNet proceeds from the increased portion of the private placement will be used to support funding of Sernova's clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial and to advance corporate/academic collaborations utilizing the Company's platform technology to treat diabetes, hemophilia and other serious disease conditions, as well as for investor relations and general corporate purposes.\n\n\n \nCompletion of the private placement is subject to the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months.\n\n\n \nThis news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.\n\n \n \nABOUT SERNOVA'S US CLINICAL STUDY\n\n\n \nThe approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are ...